Cargando…

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology

Mineralocorticoid receptor antagonists (MRAs) are a class of anti-hypertensive drugs that act by blocking aldosterone action. The aim of this study was to evaluate whether the MRAs spironolactone and eplerenone influence adrenal cortical physiology and morphology. Spontaneous hypertensive rats (SHR,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pereira, Sofia S., Carvalho, Liliana, Costa, Madalena M., Melo, Armindo, Ferreira, Isabel M. P. L. V. O., Gomez-Sanchez, Celso E., Monteiro, Mariana P., Vinson, Gavin, Pignatelli, Duarte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8074383/ https://www.ncbi.nlm.nih.gov/pubmed/33924172 http://dx.doi.org/10.3390/biomedicines9040441

Ejemplares similares

Efficacy of mineralocorticoid receptor antagonism in the acute myocardial infarction phase: eplerenone versus spironolactone
por: Fraccarollo, Daniela, et al.
Publicado: (2015)

Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings
por: Patel, Kishan A, et al.
Publicado: (2014)

Angiogenesis in the Normal Adrenal Fetal Cortex and Adrenocortical Tumors
por: Pereira, Sofia S., et al.
Publicado: (2021)

Addiction and the adrenal cortex
por: Vinson, Gavin P, et al.
Publicado: (2013)

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
por: Jaisser, Frédéric, et al.
Publicado: (2021)

Functional Zonation of the Adult Mammalian Adrenal Cortex
por: Vinson, Gavin P.
Publicado: (2016)

PS135. Effects of the mineralocorticoid receptor antagonist spironolactone in a treatment-resistant model of depression in female rats
por: Hlavacova, N, et al.
Publicado: (2016)

Mineralocorticoid Receptor Pathway Is a Key Mediator of Carfilzomib-induced Nephrotoxicity: Preventive Role of Eplerenone
por: Efentakis, Panagiotis, et al.
Publicado: (2022)

The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity
por: Nielsen, Finn Thomsen, et al.
Publicado: (2013)

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses
por: Fernet, Mireille, et al.
Publicado: (2018)

Incomplete Pattern of Steroidogenic Protein Expression in Functioning Adrenocortical Carcinomas
por: Pereira, Sofia S., et al.
Publicado: (2020)

SAT-065 Adrenal Vein Sampling Without Discontinuation Of Mineralocorticoid-Receptor Antagonist Therapy
por: Ganesh, Malini, et al.
Publicado: (2019)

Ang–Tie Angiogenic Pathway Is Distinctively Expressed in Benign and Malignant Adrenocortical Tumors
por: Oliveira, Sofia, et al.
Publicado: (2022)

The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure–HFrEF
por: Naser, Nabil, et al.
Publicado: (2023)

The emerging role of the molecular marker p27 in the differential diagnosis of adrenocortical tumors
por: Pereira, Sofia S, et al.
Publicado: (2013)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Modulation of Autophagy in Adrenal Tumors
por: Sousa, Diana, et al.
Publicado: (2022)

Mineralocorticoid Deficiency and Treatment in Congenital Adrenal Hyperplasia
por: Padidela, Raja, et al.
Publicado: (2010)

A combined CaMKII inhibition and mineralocorticoid receptor antagonism via eplerenone inhibits functional deterioration in chronic pressure overloaded mice
por: Driessen, Helen E., et al.
Publicado: (2020)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Eplerenone ethanol solvate
por: Yang, Qian, et al.
Publicado: (2008)

SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors
por: Pereira, Sofia, et al.
Publicado: (2019)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Benign adrenal adenomas secreting excess mineralocorticoids and glucocorticoids
por: Yoon, Vivienne, et al.
Publicado: (2013)

Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease
por: Liaudet, Lucas, et al.
Publicado: (2020)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
por: Chin, Eric K, et al.
Publicado: (2015)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

Spironolactone is an antagonist of NRG1‐ERBB4 signaling and schizophrenia‐relevant endophenotypes in mice
por: Wehr, Michael C, et al.
Publicado: (2017)

Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats
por: Yamamoto, Kanako, et al.
Publicado: (2018)

Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
por: Kapoor, Kapil G., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hrv0iasfe65159fj71ukkbkr8s